CM
RPRX icon

Crestline Management’s Royalty Pharma RPRX Stock Holding History

Crestline Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-101,578
Closed -$2.59M – 521
2024
Q4 		$2.59M Buy
101,578
+79,532
+361% +$2.11M 0.09% 242
2024
Q3 		$624K Buy
+22,046
New +$611K 0.03% 342
2020
Q3 		– Sell
-25,644
Closed -$1.25M – 179
2020
Q2 		$1.25M Buy
+25,644
New +$1.27M 0.23% 42

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Crestline Management's RPRX Position: Q1 2025 in Review

Crestline Management sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 101,578 shares — an estimated $2.59M sold.

Crestline Management first reported a position in RPRX in Q2 2020 and held it in 3 quarters. The position peaked at $2.59M in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Crestline Management reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 101,578 Royalty Pharma shares in Q1 2025, an estimated $2.59M.
  • Crestline Management first reported a position in Royalty Pharma in Q2 2020 and held it in 3 quarters.
  • Crestline Management's Royalty Pharma position peaked at $2.59M in Q4 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.